68Ga-labeled prostate-specific membrane antigen imaging, 68Ga-PSMA PET/CT prostate cancer detection, testing diagnostic performance of 68Ga-PSMA PET/CT, initial staging of high-risk prostate cancer patients.
Prostate cancer, stereotactic body radiotherapy (SBRT), Urethra-Sparing Stereotactic Body Radiotherapy, Urethra-Sparing Stereotactic Body Radiotherapy for Prostate Cancer, magnetic resonance guided radiotherapy (MRgRT).
Andrea Miyahira interviews Mayuko Kanayama about her team’s research on a HOXB13 variant linked to aggressive prostate cancer in African ancestry populations. Published in European…
Zach Klaassen facilitates a conversation on the continuum of care in metastatic hormone-sensitive prostate cancer (mHSPC) with Jason Hafron and Elisabeth Heath. The discussion underscores…
Alicia Morgans hosts Guru Sonpavde and Bradley McGregor to discuss the DAD trial, which uniquely combines enfortumab vedotin and sacituzumab govitecan, two antibody drug conjugates…
At the 2024 UCSF-UCLA PSMA Conference, Nicholas Nickols elucidates the evolution of prostate cancer imaging, crediting PSMA PET with transitioning it into a highly imaged…
At the 2024 UCSF-UCLA PSMA Conference, Wolfgang Fendler discusses the relevance of different PSMA PET agents in clinical practice, emphasizing that while there are various…
Alicia Morgans interviews Toni Choueiri about the results of the KEYNOTE-564 trial, marking a significant milestone in kidney cancer treatment with pembrolizumab showing an overall…
At the 2024 PSMA Conference PSMA PET and RLT: Present and Future, Louise Emmett explores enhancing prostate cancer diagnosis with PSMA PET imaging, revealing the…
Alicia Morgans discusses the evolving strategies for treating metastatic hormone-sensitive prostate cancer (mHSPC) with Karim Fizazi. Professor Fizazi critiques the traditional method of classifying metastatic…
Alicia Morgans and Rana McKay delve into the complexities of treatment sequencing for metastatic castration-resistant prostate cancer. They highlight the expansive range of available therapies,…
